Lenka Řihakova

885 total citations
17 papers, 329 citations indexed

About

Lenka Řihakova is a scholar working on Dermatology, Rheumatology and Immunology. According to data from OpenAlex, Lenka Řihakova has authored 17 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Dermatology, 7 papers in Rheumatology and 6 papers in Immunology. Recurrent topics in Lenka Řihakova's work include Dermatology and Skin Diseases (8 papers), Urticaria and Related Conditions (7 papers) and Autoimmune Bullous Skin Diseases (5 papers). Lenka Řihakova is often cited by papers focused on Dermatology and Skin Diseases (8 papers), Urticaria and Related Conditions (7 papers) and Autoimmune Bullous Skin Diseases (5 papers). Lenka Řihakova collaborates with scholars based in Canada, Argentina and France. Lenka Řihakova's co-authors include Emanuel Escher, Sylvain Chemtob, Fernand Gobeil, Martin Leduc, Gaétan Guillemette, Antony A. Boucard, Pierre Lavigne, Richard Leduc, Mannix Auger‐Messier and Tang Zhu and has published in prestigious journals such as The Journal of Immunology, Biochemistry and European Journal of Pharmacology.

In The Last Decade

Lenka Řihakova

16 papers receiving 327 citations

Peers

Lenka Řihakova

CMN

CCM

IMMUN

RHEUM

Vasanti Natarajan Norway

Haruhiko Kuno Japan

Phyllis S. Frisa United States

Donna M. Wypij United States

Mélanie Sanchez Canada

Tobias Dreker Germany

Jack R. Koehl United States

Alice Vallentin United States

Noriaki Imanishi Japan

Marie‐Thérèse Schouft France

Vasanti Natarajan Norway

Lenka Řihakova

298 ×1.6

29 ×0.4

CMN

60 ×1.1

CCM

54 ×1.0

IMMUN

11 ×0.3

RHEUM

Citations per year, relative to Lenka Řihakova Lenka Řihakova (= 1×) peers Vasanti Natarajan

Countries citing papers authored by Lenka Řihakova

Since Specialization

Citations

This map shows the geographic impact of Lenka Řihakova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lenka Řihakova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lenka Řihakova more than expected).

Fields of papers citing papers by Lenka Řihakova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lenka Řihakova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lenka Řihakova. The network helps show where Lenka Řihakova may publish in the future.

Co-authorship network of co-authors of Lenka Řihakova

This figure shows the co-authorship network connecting the top 25 collaborators of Lenka Řihakova. A scholar is included among the top collaborators of Lenka Řihakova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lenka Řihakova. Lenka Řihakova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Papp, Kim, Melinda Gooderham, Charles Lynde, et al.. (2024). Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry. Archives of Dermatological Research. 316(7). 362–362. 1 indexed citations

Gooderham, Melinda, Kim Papp, Charles Lynde, et al.. (2022). Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry. Dermatology and Therapy. 13(2). 535–553. 1 indexed citations

Papp, Kim, et al.. (2022). Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatology and Therapy. 13(1). 269–283. 2 indexed citations

Sussman, Gordon, Jacques Hébert, Wayne Gulliver, et al.. (2020). Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial. The Journal of Allergy and Clinical Immunology In Practice. 8(7). 2372–2378.e5. 26 indexed citations

Papp, Kim, Melinda Gooderham, Jennifer Beecker, et al.. (2019). Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. BMC Dermatology. 19(1). 9–9. 7 indexed citations

Sussman, Gordon, Jacques Hébert, Wayne Gulliver, et al.. (2018). Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study. SKIN The Journal of Cutaneous Medicine. 2. S54–S54.

Gulliver, Wayne, Gordon Sussman, Jacques Hébert, et al.. (2018). Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study. SKIN The Journal of Cutaneous Medicine. 2. S52–S52. 1 indexed citations

Sussman, Gordon, Jacques Hébert, Wayne Gulliver, et al.. (2018). Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU). SKIN The Journal of Cutaneous Medicine. 2. S51–S51. 2 indexed citations

Sussman, Gordon, Jacques Hébert, Wayne Gulliver, et al.. (2017). Design and rational of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU). SKIN The Journal of Cutaneous Medicine. 1. s125–s125. 1 indexed citations

10.

Sussman, Gordon, Jacques Hébert, Wayne Gulliver, et al.. (2017). Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study. SKIN The Journal of Cutaneous Medicine. 1. s127–s127. 2 indexed citations

11.

Quiniou, Christiane, Przemysław Sapieha, Isabelle Lahaie, et al.. (2008). Development of a Novel Noncompetitive Antagonist of IL-1 Receptor. The Journal of Immunology. 180(10). 6977–6987. 57 indexed citations

12.

Zhu, Tang, Fernand Gobeil, Alejandro Vazquez‐Tello, et al.. (2006). Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE₂, PAF, and LPA₁receptorsThis paper is one of a selection of papers published in this Special Issue, entitled The Nucleus: A Cell Within A Cell.. Canadian Journal of Physiology and Pharmacology. 84(3-4). 377–391. 90 indexed citations

13.

Řihakova, Lenka, Mannix Auger‐Messier, Antony A. Boucard, et al.. (2002). METHIONINE PROXIMITY ASSAY, A NOVEL METHOD FOR EXPLORING PEPTIDE LIGAND–RECEPTOR INTERACTION. Journal of Receptors and Signal Transduction. 22(1-4). 297–313. 40 indexed citations

14.

Řihakova, Lenka, Antony A. Boucard, Simon Sauvé, et al.. (2002). Angiotensin II is bound to both receptors AT₁and AT₂, parallel to the transmembrane domains and in an extended form. Canadian Journal of Physiology and Pharmacology. 80(5). 418–425. 23 indexed citations

15.

Auger‐Messier, Mannix, Antony A. Boucard, Lenka Řihakova, et al.. (2002). Residues 293 and 294 Are Ligand Contact Points of the Human Angiotensin Type 1 Receptor. Biochemistry. 41(48). 14348–14356. 46 indexed citations

16.

Řihakova, Lenka. (2001). New peptidic angiotensin II analogues their synthesis and pharmacological characterization. Knowledge UdeS (Institutional Deposit of the University of Sherbrooke). 2 indexed citations

17.

Bouley, Richard, Lenka Řihakova, Sylvie G. Bernier, et al.. (1998). N- and C-terminal structure–activity study of angiotensin II on the angiotensin AT2 receptor. European Journal of Pharmacology. 343(2-3). 323–331. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact